Meena Okera

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

George W. Sledge, Masakazu Toi, Patrick Neven et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

George W. Sledge, Masakazu Toi, Patrick Neven et al. · JAMA Oncology · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacology +17

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell et al. · New England Journal of Medicine · 2023 · 704 citations · Full text

Medicine, Oncology, Pharmacology +16

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials

Matthew P. Goetz, Meena Okera, Hans Wildiers et al. · Breast Cancer Research and Treatment · 2021 · 55 citations · Full text

Medicine, Oncology, Pharmacology +14

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy

Miguel Martín, Roberto Hegg, Sung‐Bae Kim et al. · JAMA Oncology · 2022 · 54 citations · Full text

Medicine, Oncology, Pharmacology +16